Client has a well-established product in cardiovascular space exceeding sales expectations
New analyses of Phase III clinical data reveal compelling new efficacy data in specific patient populations along unique clinical endpoints
Client seeking to identify communication messages that convey these new clinical findings while maintaining momentum with existing message platform
Series of two qualitative studies executed to evaluate new clinical data and messages
First study focused on confirming the most compelling data presentations and begin building the words and vernacular used to convey the information
Second study validated data importance and evaluated different approaches designed to communicate new clinical information while supporting the existing messaging platform
OLG implemented an objection handling scenario designed to prepare the field force for questions and/or objections related to the new analyses
Client and agency modified core product messaging in a way that highlights the new data while supporting the core brand story
OLG’s recommended approach enabled brand management and sales training to identify objections and test/validate messaging for objection handling
Brand use expanded into new indication while maintaining upward momentum
